YOLFTbeta
SynCore Biotechnology Co Ltd

SynCore Biotechnology Co Ltd

4192 · TWO · Healthcare / Biotechnology

15.60TWD-0.15 (-0.95%)

Price History

Full chart

Market Stats

Previous Close15.75
Open15.60
Day Range15.60 – 15.70
52-Week Range17.65 – 29.25
Volume13.27K
Market Cap655.83M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.33
Dividend Yield0.00%
Beta0.24
50-Day Avg18.98
200-Day Avg20.77

About

SynCore Biotechnology Co.,Ltd, engages in development and sale of healthy food, medicine inspection, and biotechnology service in Taiwan. The company is involved in the development of SB01, an injectable anti-cancer new ingredient (NCE) that is in Phase II clinical trials for the treatment of head and neck cancer; and SB02, an anti-cancer NCE, which is in preclinical research for use in the treatment of stomach cancer. It also offers SB03-Veregen, an ointment for the treatment of patients with external genital and perianal warts EGW; and SB04, a conventional drug for the treatment of age-related macular degeneration dry AMD that is in Phase II/III clinical trials. In addition, the company provides SB05-EndoTAG-1, a conventional drug for pancreatic cancer and triple-negative breast cancer that is in Phase III clinical trials. Further, it distributes cameras under the epiCam name such as hand-held color, hand-held monochrome, and veterinary fundus cameras that is used in recording the progress of ophthalmology diseases; and choroidal blood flow measurement. The company has partnerships with Aresus, MacuCLEAR Inc.; Y-YBAR; Epipole; and Sinphar Pharmaceutical Co., Ltd.; and The National Health Research Institutes NHRI. The company was incorporated in 2008 and is headquartered in Yilan City, Taiwan. SynCore Biotechnology Co.,Ltd operates as a subsidiary of Sinphar Pharmaceutical Co., Ltd.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Muh-Hwan Su
  • Employees0
  • Headquarters84 Chung Shan Road, Yilan City, Taiwan, 269, Taiwan
  • Websitehttps://syncorebio.com

Leadership

  • Dr. Muh-Hwan SuPresident & GM
  • Mr. Hui-Hung Wang M.B.A.General Manager
  • Mr. Wen-Hsin HuangVP & Head of Drug Development Department
  • Mr. Chia-Hao LiangHead of Financial & General Affairs Department and Accounting Manager
  • Mr. Ruey-Wen LinHead of Quality Assurance Department

Financials

Income Statement

Currency: TWD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue15.46M6.90M8.14M7.71M12.97M13.34M6.94M15.86M20.20M23.34M27.04M
Growth (%)--55.39%+18.06%-5.38%+68.27%+2.85%-47.97%+128.52%+27.36%+15.55%+15.88%
Cost of Revenue3.21M3.65M4.07M3.64M4.70M7.15M3.97M6.77M19.68M10.45M5.96M
Gross Profit12.25M3.25M4.07M4.07M8.27M6.19M2.97M9.09M521.00K12.89M21.09M
Gross Margin79.25%47.13%50.00%52.79%63.74%46.42%42.79%57.30%2.58%55.22%77.98%
Operating Expense218.03M246.92M264.08M305.09M424.85M401.72M459.53M195.48M37.91M70.64M68.28M
Operating Income-205.77M-243.67M-260.00M-301.02M-416.59M-395.53M-456.56M-186.40M-37.39M-57.76M-47.20M
Operating Margin-1330.82%-3532.44%-3192.58%-3906.36%-3212.67%-2965.90%-6579.65%-1175.47%-185.13%-247.49%-174.52%
EBITDA---207.45M-245.93M-353.36M-339.07M-404.13M-146.32M-17.73M-35.80M-28.00M
EBITDA Margin---2547.22%-3191.38%-2725.07%-2542.50%-5824.04%-922.78%-87.77%-153.41%-103.55%
Net Income-182.16M-162.24M-257.99M-294.13M-408.64M-398.92M-458.60M-188.67M-38.17M-54.28M-45.76M
Net Income Margin-1178.09%-2351.97%-3167.89%-3816.86%-3151.36%-2991.29%-6608.98%-1189.80%-189.01%-232.60%-169.19%
R&D169.79M208.47M224.33M257.57M380.08M363.21M422.97M157.23M3.94M28.31M24.51M
R&D as % of Total Revenue1098.13%3022.22%2754.53%3342.49%2931.16%2723.56%6095.52%991.56%19.49%121.31%90.64%
Interest Expense000982.00K2.04M3.39M2.04M2.27M784.00K302.00K173.00K
Interest Expense % of Total Revenue0.00%0.00%0.00%12.74%15.72%25.39%29.33%14.32%3.88%1.29%0.64%

Balance Sheet

Currency: TWD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets1.03B1.11B845.89M804.80M763.88M913.99M824.44M436.65M378.36M317.80M255.70M
Total Liabilities184.46M148.46M125.28M98.11M151.84M353.41M381.52M187.64M21.23M23.11M10.07M
Total Equity842.81M966.36M720.61M706.70M612.03M560.58M442.92M249.01M357.14M294.69M245.63M
Cash437.89M711.97M462.67M472.63M386.35M539.23M552.97M269.14M264.70M205.49M157.33M
Total Debt-----228.84M125.46M71.76M2.11M--
Net Debt------310.40M-427.51M-197.39M-262.58M--

Cash Flow

Currency: TWD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-156.03M-195.09M-201.96M-272.26M-418.57M-316.63M-229.86M-209.61M-82.37M-49.24M-38.33M
Investing Cash Flow-121.57M158.51M-13.91M-6.65M-3.43M-5.64M-1.64M-1.03M---
Financing Cash Flow310.70M310.70M-33.46M288.87M335.76M475.13M245.31M-73.21M78.67M--
Capital Expenditure2.02M6.69M12.16M2.99M3.55M6.02M1.64M1.04M761.00K457.00K406.00K
Free Cash Flow---215.88M-277.45M-423.46M-322.65M-231.50M-210.65M-83.13M-49.70M-38.74M
FCF to OCF--106.89%101.91%101.17%101.90%100.71%100.49%100.92%100.93%101.06%

Earnings

Report DateNov 4, 2014May 14, 2015Aug 13, 2015Nov 16, 2015
EPS Estimate-4.12-5.17-3.78-6.55
EPS Actual-3.22-3.33-2.62-4.57
Surprise21.84%35.59%30.69%30.23%
TimingAfter-hoursAfter-hoursAfter-hoursPre-market

Key Statistics & Ratios

Market Cap655.83M
Enterprise Value504.97M
Trailing P/E0.00
Forward P/E0.00
Price / Sales24.99
Price / Book2.91
EPS-1.33
Book Value6.23
Revenue (TTM)26.24M
Gross Profit (TTM)21.36M
EBITDA-41.09M
Profit Margin-178.54%
Operating Margin-219.73%
Return on Equity-19.31%
Return on Assets-11.58%
Shares Outstanding35.16M
Shares Float12.01M
Beta0.24
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Jun 29, 2023267.1646:1000